Affinivax grabs $120m Series B
Affinivax Inc, a technology platform provider for vaccines and immunotherapies, has closed $120 million in Series B financing.
Affinivax Inc, a technology platform provider for vaccines and immunotherapies, has closed $120 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination